NASDAQ · SGHT
Sight Sciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SGHT: Nov 04, 2026
Sight Sciences, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.12 | $-0.08 | $-0.14 | 4 |
| Dec 2026 | $-0.13 | $-0.08 | $-0.15 | 4 |
| Mar 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · The Motley Fool- Zacks · Oct 28, 9:00 AM EDTSight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 15, 9:23 PM EDTHC Wainwright & Co. Initiates Coverage of Sight Sciences with BuyFintel reports that on October 15, 2026, HC Wainwright & Co. initiated coverage of Sight Sciences (NASDAQGS:SGHT) with a Buy recommendation. On October 15, 2026, the latest close for the stock was $8.80, following a pre-action close of $8.25 on October 14, 2026. Over a one-we
- RTTNews · Sep 30, 6:14 AM EDTBiotech Stocks At 52-Week Highs – IOVA +31%, XERS, GRAL, ABCL, SGHT(RTTNews) – The following biotech stocks reached a 52-week high on September 29, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
- Zacks · Aug 20, 11:54 AM EDTGKOS Stock Surges 67% Year to Date: What's Driving the Rally?Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
- RTTNews · Aug 19, 8:29 AM EDTSight Sciences' TearCare Becomes First FDA-Approved MGD Therapy For Dry Eye Disease; Stock Up(RTTNews) – Sight Sciences, Inc. (SGHT), an eyecare technology company, announced that the U.S. FDA has expanded the indication for its TearCare System, making it the first and only treatment for meibomian gland dysfunction indicated to improve gland function in patients with eva
- RTTNews · Aug 19, 7:50 AM EDTSight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy(RTTNews) – Sight Sciences, Inc. (SGHT), an eyecare technology company, on Wednesday said the U.S. Food and Drug Administration has expanded the indications for its TearCare System, making it the first treatment for meibomian gland dysfunction or MGD specifically cleared to impro
- The Motley Fool · Aug 12, 7:29 PM EDTSight Sciences (SGHT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 6, 10:30 PM EDTTop Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%(RTTNews) – Today's top gainers in the biotech space include Creative Medical, boosted by a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes; Braveheart, following its IPO; Iovance, after reporting a 66% increase in second-quarter revenue; and Sight Scienc
- MarketBeat · Aug 6, 1:03 AM EDTSight Sciences Q2 Earnings Call HighlightsSight Sciences (NASDAQ:SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook a
- Zacks · Aug 5, 6:10 PM EDTSight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue EstimatesSight Sciences (SGHT) delivered earnings and revenue surprises of +46.67% and +7.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 6:00 PM EDTSight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesThe headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- RTTNews · Aug 5, 11:32 AM EDTSight Sciences Wins FDA Nod For OMNI Ultra Glaucoma Surgery System; On Track For Q4 Launch(RTTNews) – Sight Sciences, Inc. (SGHT), an eye care technology company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OMNI Ultra Surgical System, a handheld, single-use therapeutic device for minimally invasive glaucoma surgery (
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Sight Sciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.